Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness

Schizophrenia Research

Volumn 88, Issue 1-3, 2006, Pages 142-150

  Koethe, Dagmar ^a   Gerth, Christoph W ^a   Neatby, Miriam A ^a   Haensel, Anita ^a   Thies, Martin ^a,b   Schneider, Udo ^b   Emrich, Hinderk M ^b   Klosterkötter, Joachim ^a   Schultze Lutter, Frauke ^a   Leweke, F Markus ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Binocular depth inversion; Cannabis; Dronabinol; Prodromal states; Schizophrenia; THC; Visual perception

Indexed keywords

DRONABINOL;

ADULT; ARTICLE; BINOCULAR DEPTH INVERSION ILLUSION TEST; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSCIOUSNESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; FEMALE; HUMAN; MALE; NEUROMODULATION; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; STATISTICAL SIGNIFICANCE; VISUAL DISORDER; VISUAL INFORMATION;

ACUTE DISEASE; ADOLESCENT; ADULT; BRIEF PSYCHIATRIC RATING SCALE; CONSCIOUSNESS DISORDERS; DEPTH PERCEPTION; FEMALE; HALLUCINOGENS; HUMANS; MALE; PERCEPTUAL DISORDERS; PSYCHOMETRICS; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA, PARANOID; SEVERITY OF ILLNESS INDEX; TETRAHYDROCANNABINOL; VISION, BINOCULAR; VISUAL PERCEPTION;

EID: 33750623747     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.07.023     Document Type: Article

References (52)

1. Adler C.M., Goldberg T.E., Malhotra A.K., Pickar D., and Breier A. Effects of ketamine on thought disorder, working memory, and semantic memory in healthy volunteers. Biol. Psychiatry 43 11 (1998) 811-816
2. Andreasson S., Allebeck P., Engstrom A., and Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2 8574 (1987) 1483-1486
3. Angrist B., Sathananthan G., Wilk S., and Gershon S. Amphetamine psychosis: behavioral and biochemical aspects. J. Psychiatr. Res. 11 (1974) 13-23
4. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., and Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br. Med. J. 325 7374 (2002) 1212-1213
5. Arseneault L., Cannon M., Witton J., and Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 184 2 (2004) 110-117
6. Beringer K., von Baeyer W., and Marx H. Zur Klinik des Haschischrausches. Nervenarzt 5 (1932) 337-350
7. Brockhaus-Dumke A., Tendolkar I., Pukrop R., Schultze-Lutter F., Klosterkötter J., and Ruhrmann S. Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr. Res. 73 2-3 (2005) 297-310
8. D'Souza C.D., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.-T., Braley G., Gueorguieva R., and Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 8 (2004) 1558-1572
9. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., and Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 57 6 (2005) 594-608
10. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988) 605-613
11. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
12. Emrich H.M. A three-component-system hypothesis of psychosis. Impairment of binocular depth inversion as an indicator of a functional dysequilibrium. Br. J. Psychiatry 155 (1989) S37-S39
13. Emrich H.M., Weber M.M., Wendl A., Zihl J., Meyer L.V., and Hanisch W. Reduced binocular depth inversion as an indicator of cannabis-induced censorship impairment. Pharmacol. Biochem. Behav. 40 (1991) S689-S690
14. Emrich H.M., Leweke F.M., and Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to a dysregulation of the endogenous cannabinoid system. Pharmacol. Biochem. Behav. 56 (1997) 803-807
15. Freund T.F., Katona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 3 (2003) 1017-1066
16. Frith C.D., and Done D.J. Towards a neuropsychology of schizophrenia. Br. J. Psychiatry 153 (1988) 437-443
17. Frith C.D., and Done D.J. Experiences of alien control in schizophrenia reflect a disorder in the central monitoring of action. Psychol. Med. 19 2 (1989) 359-363
18. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., Klosterkötter J., and Piomelli D. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29 (2004) 2108-2114
19. Gregory R.L. Eye and brain. The Psychology of Seeing vol. 5 (1998), Oxford University Press, Oxford
20. Ha T.H., Na M.H., and Kwon J.S. Dysfunction of configural face processing in schizophrenia. Int. J. Neuropsychopharmacol. 9 S1 (2006) 161
21. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., and van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br. Med. J. 330 7481 (2005) 11
22. Huber G., and Gross G. The concept of basic symptoms in schizophrenic and schizoaffective psychoses. Recenti Prog. Med. 80 12 (1989) 646-652
23. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 2 (1987) 261-276
24. Klosterkötter J., Hellmich M., Steinmeyer E.M., and Schultze-Lutter F. Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry 58 2 (2001) 158-164
25. Leweke F.M., Kampmann C., Radwan M., Dietrich D.E., Johannes S., Emrich H.M., and Münte T.F. The effects of tetrahydrocannabinol on the recognition of emotionally charged words: an analysis using event-related brain potentials. Neuropsychobiology 37 (1998) 104-111
26. 9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology 142 3 (1999) 230-235
27. Leweke F.M., Schneider U., Radwan M., Schmidt E., and Emrich H.M. Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol. Biochem. Behav. 66 1 (2000) 175-181
28. Leweke F.M., Gerth C.W., and Klosterkötter J. Cannabis-associated psychosis: current status of research. CNS Drugs 18 13 (2004) 895-910
29. Lieberman J.A., Kane J.M., and Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91 (1987) 415-433
30. Malenka R.C., Angel R.W., Hampton B., and Berger P.A. Impaired central error-correcting behavior in schizophrenia. Arch. Gen. Psychiatry 39 1 (1982) 101-107
31. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., and Breier A. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 5 (1996) 301-307
32. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
33. Miller T.J., McGlashan T.H., Woods S.W., Stein K., Driesen N., Corcoran C.M., Hoffman R., and Davidson L. Symptom assessment in schizophrenic prodromal states. Psychiatr. Q 70 4 (1999) 273-287
34. Moreau de Tours J.-J. Du hachisch et de l'aliénation mentale, Études psychologiques (1845), Fortin et Masson, Paris
35. Overall J.E. The Brief Psychiatric Rating Scale in psychopharmacology research. Psychometric Laboratory Reports (1972), University of Texas, Galveston
36. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Reports 10 (1962) 799-812
37. Phillips L.J., Yung A.R., and McGorry P.D. Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust. N. Z. J. Psychiatry 34 (2000) S164-S169
38. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev., Neurosci. 4 11 (2003) 873-884
39. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J.C., and Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350 (1994) 240-244
40. Ruhrmann S., Schultze-Lutter F., and Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 36 S3 (2003) 162-167
41. Schneider U., Leweke F.M., Sternemann U., Weber M.M., and Emrich H.M. Visual 3D illusion: a systems-theoretical approach to psychosis. Eur. Arch. Psychiatry Clin. Neurosci. 246 (1996) 256-260
42. Schneider U., Borsutzky M., Seifert J., Leweke F.M., Huber T.J., Rollnik J.D., and Emrich H.M. Reduced binocular depth inversion in schizophrenic patients. Schizophr. Res. 53 1-2 (2002) 101-108
43. Semple D.M., Ramsden F., and McIntosh A.M. Reduced binocular depth inversion in regular cannabis users. Pharmacol. Biochem. Behav. 75 4 (2003) 789-793
44. Siomopoulos V. Amphetamine psychosis: overview and a hypothesis. Dis. Nerv. Syst. 36 6 (1975) 336-339
45. Snyder S.H. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am. J. Psychiatry 130 1 (1973) 61-67
46. Solowij N., Michie P.T., and Fox A.M. Effects of long-term cannabis use on selective attention: an event-related potential study. Pharmacol. Biochem. Behav. 40 3 (1991) 683-688
47. Stella N., Schweitzer P., and Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997) 773-778
48. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., and Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 156 4 (2002) 319-327
49. 11C]raclopride PET study of a model psychosis in humans. J. Psychiatr. Res. 34 1 (2000) 35-43
50. Wheatstone C. Contributions to the physiology of vision: I. On some remarkable, and hitherto unobserved, phenomena of binocular vision. Philos. Trans. R. Soc. Lond. 128 (1838) 371-394
51. Yung A.R., Phillips L.J., Yuen H.P., and McGorry P.D. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 67 2-3 (2004) 131-142
52. Zammit S., Allebeck P., Andreasson S., Lundberg I., and Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br. Med. J. 325 7374 (2002) 1199-1203